Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls
暂无分享,去创建一个
A. V. van Beek | R. Slart | A. Glaudemans | W. Noordzij | M. Kerstens | A. N. A. van der Horst-Schrivers | Mirte Schaafsma | A. V. D. van der Horst-Schrivers
[1] K. Pacak,et al. Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] F. Borson‐Chazot,et al. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas , 2017, Nuclear medicine communications.
[3] F. Borson‐Chazot,et al. FDOPA Patterns in Adrenal Glands: A Pictorial Essay. , 2017, Clinical nuclear medicine.
[4] R. Boellaard,et al. Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment , 2017, Clinical nuclear medicine.
[5] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[6] D. Taïeb,et al. Role of 18F‐FDOPA PET/CT imaging in endocrinology , 2014, Clinical endocrinology.
[7] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[8] E. D. de Vries,et al. Myocardial Metastases on 6-[18F] fluoro-L-DOPA PET/CT: A Retrospective Analysis of 116 Serotonin Producing Neuroendocrine Tumour Patients , 2014, PloS one.
[9] D. Rubello,et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging , 2013, Nuclear medicine communications.
[10] F. Mottaghy,et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[11] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[12] E. D. de Vries,et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.
[13] J. Czernin,et al. 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas , 2009, Journal of Nuclear Medicine.
[14] Ronald Boellaard,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[15] W. Oyen,et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[16] E. D. de Vries,et al. Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. , 2007, Clinical chemistry.
[17] Karel Pacak,et al. Phaeochromocytoma , 2005, The Lancet.
[18] D. Goldstein,et al. Diagnostic Localization of Pheochromocytoma , 2002 .
[19] H. Neumann,et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.
[20] J. Carrasquillo,et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.
[21] D. Goldstein,et al. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. , 2002, Annals of the New York Academy of Sciences.